Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
2.680
-0.030 (-1.11%)
At close: Oct 12, 2026, 4:00 PM EDT
2.800
+0.120 (4.48%)
Pre-market: Oct 13, 2026, 7:00 AM EDT
Seres Therapeutics Revenue
Seres Therapeutics had revenue of $736.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $1.88M. In the year 2025, Seres Therapeutics had annual revenue of $789.00K. That makes Seres Therapeutics the 42,486th largest company in the world by revenue and 5,802nd in the United States.
Revenue (ttm)
$1.88M
Revenue Growth
n/a
P/S Ratio
14.30
Revenue / Employee
$28,530
Employees
66
Market Cap
26.92M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 789.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
| Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
| Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
| Dec 31, 2018 | 28.27M | -3.83M | -11.94% |
| Dec 31, 2017 | 32.10M | 10.33M | 47.48% |
| Dec 31, 2016 | 21.77M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immutep | 13.79M |
| Evaxion | 7.49M |
| Kyntra Bio | 4.62M |
| BeyondSpring | 1.88M |
| IGC Pharma | 1.11M |
| ABVC BioPharma | 797.92K |
| aTyr Pharma | 190.00K |
MCRB News
- 27 days ago - Seres Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 1 month ago - Seres Therapeutics files $300M mixed securities shelf - TheFly
- 2 months ago - Seres Therapeutics Registration statement: Registration filing - Filings
- 2 months ago - Seres Therapeutics reports Q2 EPS 47c, consensus ($2.18) - TheFly
- 2 months ago - Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - GlobeNewsWire
- 2 months ago - Seres Therapeutics Earnings release: Q2 2026 - Filings